Clinical trial · Observational
Validation of FDG-PET Segmentation Tools for Tumor Delineation by Correlation of CT- and FDG-PET Volume Measurements With Histopathology of Nodal Metastases of Head and Neck Carcinomas.
NCT00782691CI-TRIAL-00001763unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Various methods of FDG-PET signal segmentation will be validated by correlation of histopathologically measured tumor dimensions in lymph node dissection specimens of head-and-neck cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT-FDG/PET scan of the head-and-neck region | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Head-and-neck cancer patients.
- description
- Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical nodes.
- interventionNames
- Other: CT-FDG/PET scan of the head-and-neck region
Primary outcomes (1)
- measure
- How accurate are the various FDG-PET segmentation tools?
- timeFrame
- Measurements are performed in conjunction with the clinical pathologist directly postoperatively.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All patients with N+ squamous cell carcinoma of the head and neck, planned for neck dissection. * Age \>18 years. Exclusion Criteria: * Pregnancy. * Women breast feeding
References
Publications (0)
Data not yet available
No reference posted for this study.